Nico Gagelmann
@nicogagelmann.bsky.social
Hematologist. Academic. Train. Think. Let's create and integral and loving actuality.
Reposted by Nico Gagelmann
Talquetamab plus Teclistamab in Multiple Myeloma (RedirecTT-1 study) nej.md/4iZNYTY
Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn
Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn
January 9, 2025 at 2:14 PM
Talquetamab plus Teclistamab in Multiple Myeloma (RedirecTT-1 study) nej.md/4iZNYTY
Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn
Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn
Reposted by Nico Gagelmann
December 11, 2024 at 6:33 PM
Reposted by Nico Gagelmann
December 10, 2024 at 8:43 PM
Reposted by Nico Gagelmann
Now @nicogagelmann.bsky.social on molecular genetics and JAKi impact on allo-HCT in MF
-1800 rux treated pts
-early allo in high-risk PMF and SMF seems to be best timing
-early allo in TP53 may offer survival benefit
-1800 rux treated pts
-early allo in high-risk PMF and SMF seems to be best timing
-early allo in TP53 may offer survival benefit
December 7, 2024 at 11:03 PM
Now @nicogagelmann.bsky.social on molecular genetics and JAKi impact on allo-HCT in MF
-1800 rux treated pts
-early allo in high-risk PMF and SMF seems to be best timing
-early allo in TP53 may offer survival benefit
-1800 rux treated pts
-early allo in high-risk PMF and SMF seems to be best timing
-early allo in TP53 may offer survival benefit
Reposted by Nico Gagelmann
